MedTrace Logo

Surfactant Replacement Guided by Early Lung Ultrasound Score in Preterm Newborns With Respiratory Distress Syndrome

NCT04775459 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 84

Last updated 2024-06-21

No results posted yet for this study

Summary

Lung immaturity is a major issue in neonatal unit.The surfactant administration improves the pulmonary prognosis in premature infants with hyaline membrane disease who escape continuous positive airway pressure (CPAP).

This surfactant had been administered at 5h25min of life in Saint Etienne from 2016 to 2019.

Studies suggest that the earlier the surfactant is administered, the more it can reduce the rate of bronchodysplasia and mortality. And some studies show a pulmonary ultrasound could help to administrate the surfactant earlier This is why a new faster strategy for diagnosing preterms needing surfactant will be usefulness and have been done in Saint-Etienne since 2021 thanks to a ultrasound score (LUS).

Conditions

Interventions

DRUG

Surfactant administration until 2020

Surfactant is administrated if Fi02 \>30% among the Guidelines of 2019

DRUG

Surfactant administration since 2021

Surfactant is administrated if Fi02 \>30% OR if score LUS \>8/18 among the literature

Sponsors & Collaborators

  • Centre Hospitalier Universitaire de Saint Etienne

    lead OTHER

Principal Investigators

  • Aurelie CANTAIS, MD · CHU de Saint-Etienne

Eligibility

Max Age
1 Day
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-01
Primary Completion
2021-05-31
Completion
2021-05-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04775459 on ClinicalTrials.gov